Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269101 | 0.86 | MEN1 (0.60) | P2RX7ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL22103681 | 0.83 | POLB (0.64) | P2RX7KDM4EALDH1A1KMT2AMEN1 | |
| Acetic Acid SCHEMBL19585268 | 0.82 | P2RX7 (0.47) | P2RX7KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL9016343 | 0.82 | RAB9A (0.46) | P2RX7KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL19151120 | 0.82 | BRD4 (0.54) | P2RX7KDM4EALDH1A1POLBBRD4 | |
| SCHEMBL12304228 | 0.82 | TP53 (0.54) | P2RX7KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL23591985 | 0.80 | PTPN1 (0.51) | P2RX7KDM4EKMT2AMEN1NPC1 | |
| SCHEMBL16794590 | 0.80 | KDR (0.42) | KDM4EALDH1A1KMT2AMEN1POLB | |
| SCHEMBL9859896 | 0.80 | RAB9A (0.56) | KDM4EALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL7888919 | 0.80 | NPC1 (0.47) | KDM4EALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | claimed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3668882-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| CN-106661018-B | Pyrrolo- [2,3-C] pyridine as neurofibrillary tangles imaging agent | 默沙东公司 | 2019-07-19 | — | — | CN | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2019034890-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| CN-106661018-A | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | 默沙东公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2632898-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | Biogen Idec MA Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012058645-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | P2RX7 1047/4885KDM4E 1865/4885ALDH1A1 1618/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | P2RX7 1088/4885KDM4E 2420/4885ALDH1A1 1598/4885 |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | P2RX7 2652/4885KDM4E 743/4885ALDH1A1 719/4885 |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | PDCD2L, NOTUM, OXA1L | P2RX7 958/4885KDM4E 203/4885ALDH1A1 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.